Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9122889 | 1.00 | CYP2D6 (0.44) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL10560492 | 1.00 | CYP2D6 (0.44) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL9730561 | 0.98 | CYP2D6 (0.47) | CYP2D6MEN1LMNATP53KMT2A | |
| Hydrochloric Acid SCHEMBL1190314 | 0.98 | KMT2A (0.42) | CYP2D6MEN1LMNATP53KMT2A | |
| SCHEMBL588857 | 0.93 | — | — | |
| SCHEMBL1401177 | 0.93 | — | — | |
| SCHEMBL10059315 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL8177494 | 0.91 | GHSR (0.35) | CYP2D6MEN1LMNATP53KMT2A | |
| Hydrochloric Acid SCHEMBL22495082 | 0.91 | GHSR (0.35) | CYP2D6MEN1LMNATP53KMT2A | |
| Hydrochloric Acid SCHEMBL20520978 | 0.91 | GHSR (0.35) | CYP2D6MEN1LMNATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187702-B2 | Sulfonamideurea compounds | INFLAZOME LIMITED (IE) | 2025-01-07 | — | — | US | disclosed |
| CN-118619877-A | Oxalyl diamine derivatives and uses thereof | 中国科学院上海药物研究所 | 2024-09-10 | — | — | CN | disclosed |
| EP-1656983-B1 | Process for deacidification of a gas with an absorbing solution and fractional regeneration | IFP ENERGIES NOW (FR) | 2024-01-24 | — | — | EP | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021076448-A1 | SOMATOSTATIN MODULATORS FOR TREATING PITUITARY ADENOMAS | Crinetics Pharmaceuticals, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-0232612-B1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | Dr. Lo. Zambeletti S.p.A. (IT) | 1990-04-04 | — | — | EP | disclosed |
| EP-0345629-A2 | Condensed diazepinones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1989-12-13 | — | — | EP | disclosed |
| US-4873236-A | BRADYCARDIAL AGENTS | DR. KARL THOMAE GMBH (DE) | 1989-10-10 | — | — | US | disclosed |
| EP-0156191-B1 | CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1989-07-19 | — | — | EP | disclosed |
| US-4801585-A | Cyclic carboxamide derivatives and their use as analgesics | DR.LO.ZAMBELETTI S.P.A. (IT) | 1989-01-31 | — | — | US | disclosed |
| EP-0273239-A1 | Condensed diazepinones, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1988-07-06 | — | — | EP | disclosed |
| EP-0232612-A1 | Azacyclic compounds, processes for their preparation, and their use as pharmaceuticals | Dr. Lo. Zambeletti S.p.A. (IT) | 1987-08-19 | — | — | EP | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0156191-A2 | Condensed diazepinones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-10-02 | — | — | EP | disclosed |
| US-3980788-A | XANTHENYL COMPOUNDS | SMITHKLINE CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | CYP2D6 394/4885MEN1 3286/4885LMNA 1529/4885 |
| US-12187702-B2 | Sulfonamideurea compounds | NLRP3, NOD1, NLRP1 | CYP2D6 227/4885MEN1 3371/4885LMNA 1367/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CYP2D6 4302/4885MEN1 3335/4885LMNA 3011/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CYP2D6 2230/4885MEN1 3630/4885LMNA 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.